S-1/A: Quoin Pharmaceuticals Announces Proposed Offering of Ordinary Shares and Warrants

Quoin Pharmaceuticals is offering up to 19,230,769 ordinary shares represented by American Depositary Shares (ADSs) along with warrants in a reasonable best efforts offering.

Summary

• Quoin Pharmaceuticals is undertaking a best efforts offering of up to 19,230,769 ADSs, along with Series F and Series G warrants to purchase additional ADSs.
• The assumed combined public offering price is $0.78 per ADS and accompanying warrants, based on the closing price of Quoin's ADSs on December 9, 2024.
• Each Series F Warrant will have an exercise price equal to 100% of the public offering price per ADS and accompanying Warrants, will be exercisable upon issuance, and will expire two years from the date of issuance.
• Each Series G Warrant will have an exercise price of equal to 100% of the public offering price per ADS and accompanying Warrants, will be exercisable upon issuance, and will expire five years from the date of issuance.
• Pre-funded warrants are also being offered to purchasers whose acquisition of ADSs would result in beneficial ownership exceeding 4.99%.
• Each Pre-Funded Warrant will be immediately exercisable for one ADS at an exercise price of $0.0001 per ADS.
• Maxim Group LLC is acting as the exclusive placement agent for the offering.
• The offering is expected to close in a single closing, and will terminate on January 11, 2025, unless fully subscribed or terminated earlier.
• Net proceeds are intended for general corporate purposes, including operating expenses, research and development, working capital, and potential acquisitions.
• The company's officers and directors may participate in the offering.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the capital raise is necessary for the company's operations, the terms of the offering, including the potential dilution and the lack of a guaranteed raise, present risks for investors.

Positives

• The offering provides Quoin Pharmaceuticals with additional capital for general corporate purposes, including research and development.
• The inclusion of warrants may make the offering more attractive to investors.
• The potential participation of officers and directors could signal confidence in the company's prospects.

Negatives

• The offering is on a 'reasonable best efforts' basis, meaning there is no guarantee that the company will raise the full amount sought.
• The offering may cause dilution to existing shareholders.
• There is no established public trading market for the warrants.
• The company's management has broad discretion over the use of the net proceeds.
• The company may need to raise additional funding in the future.
• The assumed offering price may not be indicative of the final offering price.

Risks

• The company may not raise the amount of capital it believes is required for its business plans.
• Investors may experience immediate and substantial dilution in the net tangible book value of the shares they purchase.
• The offering may cause the trading price of the company's ADSs to decrease.
• The company's management will have broad discretion over the use of the net proceeds from the offering.
• There is no public market for the pre-funded warrants or the warrants being offered.
• The warrants may not have any value if the market price per ADS does not exceed the exercise price of the warrants during the period when the warrants are exercisable.
• The company's failure to meet the continued listing requirements of The Nasdaq Capital Market could result in a delisting of its ADSs.

Future Outlook

The company intends to use the net proceeds from the sale of the Securities under this prospectus for general corporate purposes, which may include operating expenses, research and development, including clinical and pre-clinical testing of our product candidates, working capital, future acquisitions and general capital expenditures.

Industry Context

Quoin Pharmaceuticals is operating in the specialty pharmaceutical industry, focusing on rare and orphan diseases. This offering is a common method for clinical-stage companies to raise capital to fund ongoing research and development activities.

Comparison to Industry Standards

• Comparable companies raising capital through similar offerings include other clinical-stage biotech firms like Athersys and BioTime.
• The terms of the offering, including the warrant coverage and placement agent fees, are generally in line with industry standards for companies of Quoin's size and stage of development.
• The use of proceeds for clinical trials and general corporate purposes is typical for companies in this sector.

Stakeholder Impact

• Shareholders may experience dilution as a result of the offering.
• Employees will benefit from the continued funding of the company's operations.
• Patients with rare skin diseases may benefit from the company's research and development efforts.
• The company's suppliers and creditors will be impacted by the company's financial performance.

Next Steps

• The company will continue to execute its clinical development programs for QRX003 and QRX004.
• The company will work with Maxim Group LLC to market and sell the securities offered in the offering.
• The company will seek to obtain regulatory approvals for its product candidates.
• The company will explore potential business development opportunities.

Key Dates

Keywords

ADS, warrants, offering, Quoin Pharmaceuticals, capital raise, securities, placement agent, ordinary shares, pre-funded warrants, clinical trials, QRX003, QRX004, Netherton Syndrome, RDEB